Authors

Latest:

Day in the Life of an Oncology/Hematology Fellowship Program Director

Trainees have sat in this hot seat at the front of the room for decades. It's not really warm, of course. This is where the fellow sits who is asked to review the findings, come up with a differential diagnosis, and devise a plan for the case in question.

Joanne Mortimer, MD

Latest:

Dr. Mortimer on the Potential Benefit of Tucatinib Plus ADCs in HER2+ Breast Cancer

Joanne Mortimer, MD, discusses the potential benefit of tucatinib plus antibody-drug conjugates in HER2-positive breast cancer.

Joanne Xiu, PhD

Latest:

Dr. Xiu on HR Expression in Uterine Carcinosarcoma

Joanne Xiu, PhD, research scientist, Caris Life Sciences, discusses findings from a study that showed hormone receptor (HR) expression is present in a subset of patients with uterine carcinosarcoma.

Joaquim Bellmunt, MD, PhD

Latest:

Dr Bellmunt on Avelumab Maintenance in Advanced Urothelial Carcinoma With Low Tumor Burden

Joaquim Bellmunt, MD, PhD discusses findings from a post-hoc analysis for avelumab maintenance in advanced urothelial carcinoma with low tumor burden.

Jochen H. Lorch, MD

Latest:

Dr. Lorch on the Treatment of Medullary Thyroid Cancer

Jochen H. Lorch, MD, director, Thyroid Cancer Center, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses the current treatment landscape of medullary thyroid cancer.

Jodie Barr, DO

Latest:

Dr. Barr on Temozolomide and Capecitabine in Neuroendocrine Tumors

Jodie Barr, DO, hematologist/oncologist, Lawrence Memorial Hospital, discusses the combination of temozolomide and capecitabine in neuroendocrine tumors (NETs).

Jody Sheehan Garey, PharmD

Latest:

Compatibility Check: Can Precision Medicine and Pathways Co-Exist?

One of the most widely talked about trends in healthcare is precision medicine, which uses detailed genetic information about a patientâ€™s cancer to more precisely treat the disease, effectively targeting the tumor. This heightened awareness raises an important question: are precision medicine and pathways compatible?

Joe M. O'Sullivan, MD, FRCPI, FFRRSCI, FRCR, Queens University Belfast

Joe OSullivan, MD

Latest:

Dr. O'Sullivan on Safety Profile of Radium-223

Joe O'Sullivan, MD, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Centre for Cancer Research and Cell Biology, at Queenâ€™s University Belfast, discusses toxicities associated with radium-223 dichloride for patients with metastatic castration-resistant prostate cancer.

Joe OSullivan, MD, FRCPI, FFRRCSI, FRCR, The Northern Ireland Cancer Centre, Belfast City Hospital

Joe OSullivan, MD, Queen's University

Joel Neal, MD

Latest:

Dr. Neal Debates Whether Alectinib Will Become the Standard Frontline Therapy for ALK+ NSCLC

Joel Neal, MD, an assistant professor of medicine and oncology at Stanford Medicine, discusses whether, if approved by the FDA, alectinib (Alecensa) will become the frontline standard of care for patients with ALK-positive non–small cell lung cancer (NSCLC).

Joel Neal, MD, PhD

Latest:

Dr. Neal on the FDA Approval of Mobocertinib in EGFR Exon 20 Insertion+ NSCLC

Joel Neal, MD, PhD, discusses the FDA accelerated approval of mobocertinib in EGFR exon 20 insertion–positive non–small cell lung cancer.

Joel Silver, MD

Latest:

Dr. Silver Talks About Advances in Treatment of Hematological Cancers

Joel Silver, MD, a medical oncologist and a member of the board of directors of Regional Cancer Care Associates, discusses the progress being made in the treatment of hematological cancers, especially in multiple myeloma.

Joel Stettler, BSN, RN, OCN

Latest:

Joel Stettler on Procedures for Fall-Risk Patients

Joel Stettler, BSN, RN, OCN, Moffitt Cancer Center, discusses procedures implemented at his institution for patients who are at risk for falls.Â

Johan F. Vansteenkiste, MD, PhD, Leuven University Hospital

Johan Vansteenkiste, MD,PhD

Latest:

Dr. Johan Vansteenkiste on Atezolizumab in NSCLC

Johan F. Vansteenkiste, MD, PhD, professor of Internal Medicine at Katholieke Universiteit Leuven, Belgium, discusses the primary analysis of the phase II POPLAR study, which looked at atezolizumab versus docetaxel in patients with nonâ€“small cell lung cancer (NSCLC).

Johann de Bono, PhD, MB, ChB, Institute of Cancer Research, Royal Marsden Hospital

Johanna Bendell, MD

Latest:

Dr. Bendell Discusses a Phase III Study of Apatinib in Gastric Cancer

Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses a randomized phase III placebo-controlled trial that explored apatinib as a treatment for patients with advanced gastric cancer.